Atlas Trials

A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy

Clinical trial NCT06907875 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06907875
Sponsor
Epicrispr Biotechnologies, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Facioscapulohumeral Muscular Dystrophy
Start date
2025-05-08
Primary completion
2027-07-07
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.